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CORRECTION
MEDICAL SCIENCES
Correction for “Characterizing the developmental pathways
TTF-1, NKX2–8, and PAX9 in lung cancer,” by David S. Hsu,
Chaitanya R. Acharya, Bala S. Balakumaran, Richard F. Riedel,
Mickey K. Kim, Marvaretta Stevenson, Sascha Tuchman, Sayan
Mukherjee, William Barry, Holly K. Dressman, Joseph R. Ne-
vins, Scott Powers, David Mu, and Anil Potti, which appeared in
issue 13, March 31, 2009, of Proc Natl Acad Sci USA (106:5312–
5317; ﬁrst published March 11, 2009; 10.1073/pnas.0900827106).
The authors note, “We wish to bring to your attention an issue
regarding our PNAS publication referenced above. The focus
of the paper was the characterization of the signaling pathways
of TTF-1, NKX2–8, and PAX9 in lung cancer using a tran-
scriptome-based approach. As such, gene expression signatures
representative of the activation of individual transcription factors
(TFs), TTF-1, NKX2–8, or PAX9 were developed and were found
to have prognostic implication in a data set of clinically anno-
tated lung cancer specimens (Figs. 1–3).
“A second validation was then performed in an independent
data set of lung cancer specimens. However, the source publi-
cation of the gene expression dataset (1) was retracted by the
paper’s authors in March 2011, calling into question the validity
of the results using this dataset as described in Fig. 4, and with
a subset of the data in Fig. S7. In addition, we have not been able
to reproduce results reported in Fig. S6, which contains a subset
of the data shown in Fig. 4. Given this ﬁnding, we believe that the
affected ﬁgure in the paper (Fig. 4), as well as the data in Figs. S6
and S7 that report an analysis of a subset of the data in Fig. 4, are
no longer valid.
“Finally, we also note that a speciﬁc portion of analysis (i.e.,
cisplatin sensitivity prediction) presented in Fig. 5 can no longer
be supported, because the publication describing the cisplatin
signature has been retracted (2). However, this issue does not
alter the validity of the Fig. 5 data describing the unsupervised
hierarchical clustering of 56 lung cancer cell lines using the three
TF signatures (Fig. 5A Upper) and the experimental determi-
nation of cisplatin sensitivity (Fig. 5B Right). More importantly,
the ﬁnal conclusion of Fig. 5, which is that activation of the TF
is correlated with sensitivity to cisplatin (Fig. 5B Right), remains
unaltered. Importantly, we do not believe that this correction
alters the primary conclusions of the paper.”
1. Potti A, et al. (2006) A genomic strategy to reﬁne prognosis in early-stage non-small-
cell lung cancer. N Engl J Med 355:570–580.
2. Hsu DS, et al. (2007) Pharmacogenomic strategies provide a rational approach to the
treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:
4350–4357.
www.pnas.org/cgi/doi/10.1073/pnas.1111196108
RETRACTION
APPLIED PHYSICAL SCIENCES, BIOPHYSICS AND COMPUTATIONAL
BIOLOGY
Retraction for “Phospholipid bilayers are viscoelastic,” by
Christopher W. Harland, Miranda J. Bradley, and Raghuveer
Parthasarathy, which appeared in issue 45, November 9, 2010,
of Proc Natl Acad Sci USA (107:19146–19150; ﬁrst published
October 25, 2010; 10.1073/pnas.1010700107).
The authors wish to note the following: “We have determined
that the conclusions stated in our paper are an artifact of errors
of analysis. Our methods involved determining the rheological
properties of lipid bilayers from analysis of the trajectories of
lipid-anchored particles. Errors related to the particle-tracking
methods we used generated an artifactual elastic-like signature.
“The imprecision in tracking resulted from determining the
position of each particle by ﬁtting the logarithm of the particle’s
intensity proﬁle to a quadratic function. Directly ﬁtting the in-
tensity to a Gaussian form is considerably less sensitive to noise
and signal intensity. This improved ﬁtting reduces positional
uncertainty in test images from around 30 nm to a few nm and,
applied to our membrane data, completely eliminates the ‘elas-
tic’ response. Moreover, adding 30 nm of random error to pre-
cisely tracked images reproduces the reported elastic signature.
Therefore, our data indicate that lipid membranes show a purely
viscous character over the entire frequency range examined. Our
initial assessments of particle tracking algorithms were not suf-
ﬁciently stringent, leading to an overestimate of our tracking
precision and the use of inadequate ﬁtting methods.
“The artifactual elastic response we reported showed a feature
at the chain ordering transition temperature of the lipid mem-
branes examined. We are not certain what aspect of the images,
when imprecisely tracked, led to this feature. We suspect that
motions of the particles perpendicular to the membrane plane
may be responsible.
“The conclusions of the paper are wrong and, regrettably, we
must retract the work. We sincerely apologize for any confusion
that our report may have caused.”
Christopher W. Harland
Miranda J. Bradley
Raghuveer Parthasarathy
www.pnas.org/cgi/doi/10.1073/pnas.1111381108
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Communicated by Aziz Sancar, University of North Carolina, Chapel Hill, NC, January 26, 2009 (received for review November 17, 2008)
We investigated the clinical implications of lung developmental
transcription factors (TTF-1, NKX2–8, and PAX9) that we recently
discovered as cooperating oncogenes activated by way of gene
amplification at chromosome 14q13 in lung cancer. Using stable
transfectants of human bronchial epithelial cells, RNA expression
profiles (signatures) representing activation of the biological path-
ways defined by each of the 3 genes were determined and used to
risk stratify a non-small-cell lung cancer (NSCLC) clinical data set
consisting of 91 early stage tumors. Coactivation of the TTF-1 and
NKX2–8 pathways identified a cluster of patients with poor sur-
vival, representing 20% of patients with early stage NSCLC,
whereas activation of individual pathways did not reveal signifi-
cant prognostic power. Importantly, the poor prognosis associated
with coactivation of TTF-1 and NKX2–8 was validated in 2 other
independent clinical data sets. Furthermore, lung cancer cell lines
showing coactivation of the TTF-1 and NKX2–8 pathways were
shown to exhibit resistance to cisplatin, the standard of care for the
treatment of NSCLC. This suggests that the cohort of patients with
coactivation of TTF-1 and NKX2–8 pathways appears to be resis-
tant to standard cisplatin therapy, suggesting the need for alter-
native therapies in this cohort of high-risk patients.
gene expression  lung cancer  transcription factors
The complexity of the oncogenic process involving the somaticacquisition of large numbers of mutations, coupled with the
varied host genetic constitution, produces a disease of enormous
complexity. The ability to dissect this complexity by better under-
standing models of carcinogenesis, lineage dependence, and onco-
gene addiction is critical for developing new effective therapeutic
strategies.
There is strong evidence for the involvement of developmental
and cell lineage-dependent processes in the development of human
tumors. For example, multiple genes (e.g., AML1, PML-RAR
fusion gene, and PAX5) that are critical to hematopoietic progen-
itor cell development are frequently altered in hematologic malig-
nancies (1). Similar examples exist in cell proliferation and differ-
entiation events that lead to melanoma (2). In contrast to the
oncogene addiction model that invokes a tumor-specific gain-of-
function event (3), the lineage-survival oncogene model (4) pro-
poses that tumors may become highly dependent on survival
mechanisms that are built into the lineage precursor cells during
development and that alteration of the genes involved in these
survivalmechanisms could provide selective advantage for evolving
tumor cells.
Despite the large number of transcription factors involved in
mammalian lung development, the role of these factors in lung
cancer progression, particularly non-small-cell lung cancer
(NSCLC), and their clinical relevance have not been comprehen-
sively evaluated. Recently, we discovered and functionally charac-
terized a novel, recurrent amplicon located at 14q13.3 that appears
to harbor lung cell lineage-specific oncogenes due to its preferential
occurrence in lung cancer and the role that these 3 genes play in lung
development (5). High-resolution quantitative PCRmapping of the
commonly amplified region revealed genes encoding 3 transcription
factors in the 413-kb core region of the amplicon: TTF-1,NKX2–8,
and PAX9. Both TTF-1 and NKX2–8 are known to mediate lung
development and maturation (5, 6). Similarly, PAX9 is also likely
involved in lung development as evident by its expression in fetal
lung tissue and the diverse negative impact on organogenesis in
knockout animals (7). Whereas overexpression of individual mem-
bers of this 3-gene set in the core region of the amplicon was
ineffective in stimulating proliferation, combinatorial overexpres-
sion of the genes led to significant proliferation of premalignant
human bronchial epithelial cells, implicating oncogene cooperation
for the 3 coamplified lung development regulators. Furthermore,
our reported RNAi knockdown experiments in concert with other
reports establish that each of these 3 genes can have essential tumor
maintenance function (5, 8, 9).
To investigate the impact of the 3 collaborating lung cell lineage
oncogenes on clinical outcome, we adapted a validated strategy that
utilizes gene expression profiles as ameasure of the consequence of
an activated oncogenic pathway, irrespective of how the signaling
pathway might have been altered. Thus, even if the known onco-
gene is not mutated, but rather another component of the pathway
is altered, the expression profile will likely still detect the biological
alteration. Building upon this approach, here we describe a signif-
icant correlation of lung tumors with dual activation of the biolog-
ical pathways directed by both TTF-1 and NKX2–8 with poor
survival. Furthermore, we demonstrate that lung cancer cells
possessing coactivated TTF-1 and NKX2–8 pathways exhibit cis-
platin resistance, suggesting the need for alternative therapies in this
cohort of high-risk patients.
Results
Gene Expression Signatures That Reflect the Activity of TTF-1, NKX2–8,
and PAX9. Using gene expression levels of TTF-1 (Probe IDs
207771at, 207772sat), NKX2–8 (Probe ID 207451at), and PAX9
(207059at), we first explored the possibility that individual gene
expression levels of the developmental transcription factors may
reveal correlations with clinical parameters. To test this hypothesis,
we chose survival in patients with surgically resected stage I
NSCLC. Supporting information (SI) Fig. S1 and Fig. S2 depict an
analysis of transcription factor status in a cohort of NSCLC tumors
(n  91) that included comparable numbers of squamous cell
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carcinoma and adenocarcinoma (GSE3141). Importantly, none of
these patients had received adjuvant chemotherapy. Kaplan–Meier
survival analysis shows that no statistically significant differencewas
detected between high or low expression level of NKX2–8, TTF-1,
and PAX9 (Fig. S1) or when combinations of high or low expression
level of NKX2–8/TTF-1 were examined (Fig. S2), suggesting that
gene expression levels of these transcription factors hold no defin-
itive prognostic implications.
As gene expression levels of NKX2–8, TTF-1, and PAX9 could
not be used to identify a clinically relevant phenotype, we hypoth-
esized that signatures representative of coordinated activation of
NKX2–8, TTF-1, and PAX9 pathways may be more informative.
Using oncogene-immortalized, premalignant lung epithelial cells
(BEAS-2B), pathway signatures were developed that embodied the
activation of TTF-1, NKX2–8, or PAX9. Individual genes were
retrovirally transduced into BEAS-2B cells for stable expression
anduninfected cells were eliminated by drug selection.Quantitative
assays evaluating overexpression of TTF-1, NKX2–8, and PAX9
confirmed the biochemical activation of each gene (Fig. 1A).
Gene expression signatures represented by metagenes, which
represent groups of genes that together exhibit a consistent pattern
of expression in a collection of samples, were identified and
correlated to the observable phenotype of activation of a transcrip-
tion factor (e.g.,TTF-1,NKX2–8, orPAX9), as described previously
(10). This analysis selects a set of genes whose expression levels are
most highly correlated with the classification of cell lines into
oncogene activated/deregulated vs. control (Fig. 1B Upper). The
dominant principal component from such a set of genes then
defines a relevant phenotype-related metagene, and regression
models assign the probability of TTF-1, NKX2–8, or PAX9 activa-
tion in an independent validation set of tumor or cell line samples.
Fig. 1B (Upper) illustrates the gene expression patterns that
reflect the activity of the 3 transcription factors (TTF-1, NKX2–8,
and PAX9) coded for by 3 coamplified genes in the 14q13.3
amplicon. Each individual signature distinguishes cells expressing
the transcription factors from control cells (Fig. 1BLower). As such,
this result suggests that these gene expression signatures represent
tools to accurately profile the biological pathway status defined by
each transcription factor. Importantly, gene annotation of the
individual gene expression profiles using GATHER (11) further
demonstrated that the TTF-1, NKX2–8, and PAX9 signatures are
composed of genes/pathways that have previously been shown to be
critical in both embryonal tissue development (JAK/STAT, Wnt,
BMP, and Hedgehog) (12–15) and more specifically lung develop-
ment (MAPkinase, PI3kinase, and JAK/STAT) (Table S1) (15–17).
TTF-1, NKX2–8, and PAX9 Activation Correlates with Molecular and
Pathologic Phenotypes of NSCLC. Using robust predictors of activa-
tion of TTF-1,NKX2–8, and PAX9, we explored the possibility that
signatures representative of deregulated developmental pathways
may further dissect lung cancer phenotypes. Fig. 2A depicts an
analysis of pathway status of the 3 transcription factors in a cohort
of 91 NSCLC tumors described above (GSE3141). Following
prediction of transcription factor activation probabilities, the re-
sulting probabilities of a tumor having activation of TTF-1,
NKX2–8, or PAX9 pathways in the NSCLC cohort were grouped
using hierarchical clustering. Three distinct clusters were observed,
with cluster 1 consisting of NKX2–8/TTF-1 coactivation, cluster 2
consisting of NKX2–8 activation, and cluster 3 consisting of PAX9/
TTF-1 coactivation (Fig. 2A). Interestingly, PAX9, TTF-1, and
NKX2–8 activation status correlates with the tissue subtype of
non-small-cell lung cancer; the majority of the adenocarcinoma
samples exhibit a high probability of PAX9 and TTF-1 activation
(Fig. 2B) relative to the squamous cell carcinoma samples, in line
with published reports that TTF-1 protein expression is higher in
adenocarcinoma than in squamous cell carcinoma (18–21). In
contrast to TTF-1 and PAX9, NKX2–8 deregulation is more prom-
inent in squamous cell carcinomas. (Fig. 2B). Furthermore, an
examination of KRAS and epidermal growth factor receptor
(EGFR)mutational status in these tumors identified 11 of 91 (12%)
samples with KRAS (codon 12) mutations (11/45, 24.4% of ade-
nocarcinomas) and only a small number of samples, 6 of 91 (6.5%),
contained EGFRmutations (exons 18, 19, and 21), all restricted to
adenocarcinomas (Fig. 2A), consistent with current literature (22,
23). Interestingly, among the 2 largest clusters of patients, only 3 of
11 (27%) of KRAS mutations were confined to tumors with
NKX2–8 andTTF-1 coactivation while 5 of 11 (45%)were confined
to tumors with coactivated PAX9 and TTF-1, suggesting that the
specific patterns of coactivation of developmental transcription
factors (TTF-1, NKX2–8, and PAX9) are independent of either
KRAS or EGFR mutational events.
We further explored the pathway coactivation of NKX2–8 and
TTF-1 coactivation in a series of tumors in which KRAS was
spontaneously activated by homologous recombination in adult
mice (24). In these animal lung tumors, TTF-1 and NKX2–8
coactivation was observed in a subgroup, similar to the pattern of
coactivation seen in human lung tumors. Importantly, not all of the
KRAS-dependent murine tumors had evidence of TTF-1/NKX2–8
coactivation (Fig. S3). Taken together, these results further support
the hypothesis that coactivation of the developmental pathways
TTF-1 andNKX2–8 represents an important, potentially aggressive
phenotype of NSCLC that is not defined just by the RAS pathway.
Fig. 1. (A) Individual genes (NKX2–8, PAX9, and TTF-1) were retrovirally
transfected into BEAS-2B cells for stable expression and uninfected cells were
eliminated by drug selection. Quantitative assays evaluating TTF-1, NKX2–8,
and PAX9 activation confirmed the overexpression of each gene by Western
analysis (Upper) and RT-PCR (Lower). V, vector; P, PAX9; T, TTF-1; N, NKX2–8.
(B) (Upper) An image intensity display of the expression levels of genes most
highly weighted in a profile differentiating control cell lines from cell lines
representative of activated TTF-1, NKX2–8, and PAX9. (Lower) The fitted
classification probabilities of the samples used to develop the predictor. Each
cell line in the training set is indicated by a sample index number and is color
coded, with blue indicating control cell lines and red indicating transfected
cell lines for a given signature.
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TTF-1 and NKX2–8 Coactivation and Survival Patterns in NSCLC.Using
survival as a clinically relevant phenotype, we investigated the
extent to which analysis of the activation status of the developmen-
tal pathways delineates prognosis in lung cancer. Kaplan–Meier
survival curves of the 3 independent clusters identified in Fig. 2A
were analyzed independent of tumor histology (squamous vs.
adenocarcinoma); concerted activation of TTF-1 and NKX2–8
target genes (cluster 1) identified a population of patients (22/91,
24%) with poor survival when compared to cluster 2 (activation of
NKX2–8 only) (P  0.002) or cluster 3 (activation of PAX9 and
TTF-1) (P 0.02) (Fig. 3). When subgroup analyses involving only
activation of any one transcription factor were performed, no
statistically significant survival difference was observed (P  0.3)
(Fig. S4). Importantly, the poor prognosis cluster of patients
represented by coactivation of both TTF-1 and NKX2–8 had a
survival pattern similar to that of patients with metastatic NSCLC
(Fig. S5, n 37), suggesting that the coactivation of developmental
pathways TTF-1 and NKX2–8 in a group of early stage patients
portends a poor overall survival that phenotypically mimics meta-
static disease.
Further validation of the prognostic importance of cluster 1
(TTF-1, NKX2–8 coactivation) was performed in an independent
pooled analysis based on tumor samples derived from 2 large
independent data sets, 84 adenocarcinoma samples (GSE3593) and
130 squamous carcinoma samples (GSE4573) (25, 26). In this large
validation cohort (n 214), coderegulation of TTF-1 andNKX2–8
pathways was also associated with the worst outcome, when com-
pared to other combinations of transcription factor activation
(clusters 2 and 3) (Fig. 4 A and B). Importantly, a similar trend was
seenwhenwe repeated the analysis using either theGSE3593 or the
GSE4573 data set alone (Fig. S6 and Fig. S7). As further confir-
mation, univariate and multivariate analyses (Table 1) revealed a
statistically significant (univariate Cox proportional hazards model,
P  0.009) prognostic implication of NKX2–8/TTF-1 coactivation
(cluster 1), independent of traditional prognostic criteria such as
tumor size, vascular invasion, lymph node status, or stage of disease
(multivariate Cox proportional hazards model, P  0.03).
As such, it appears that the ability to integrate developmental
pathway analysis by identifying patterns of coderegulation does
provide amechanism to better categorize patients with lung cancer.
Importantly, this analysis demonstrates the strong association of
TTF-1 andNKX2–8 coactivation in non-small-cell lung cancer with
an adverse clinical outcome.
TTF-1 and NKX2–8 Coactivation and Resistance to Cisplatin Therapy.
An ability to identify patients at high risk for an adverse outcome
also emphasizes the need for better therapeutic strategies, partic-
NKX2-8                  PAX9                     TTF-1
B
NKX2-8
PAX9
TTF1
Cluster 1                                     Cluster 2                                              Cluster 3             Cluster 4    
A
Fig. 2. (A) Unsupervised hierarchical clustering of
patients with clinical stage I NSCLC identifies unique
patterns of TTF-1, NKX-2, and PAX9 coactivation (red,
high level of activation; blue, low level of activation) in
our cohort of 91NSCLC (GSE3141) tumors that includes
comparable numbers of squamous cell carcinoma (yel-
low) and adenocarcinoma (green). *, KRAS and EGFR
mutations. (B) Prediction of PAX9, TTF-1, and NKX2–8
activation in NSCLC and correlationwith the histologic
subtypeofNSCLC. Themajorityof theadenocarcinoma
samples exhibit a high probability of PAX9 (P 0.001,
Mann–Whitney) and TTF-1 (P 0.005,Mann–Whitney)
activation relative to the squamous cell carcinoma
samples. This is in contrast to NKX2–8 deregulation,
which is prominent in squamous cell carcinomas (P 
0.002, Mann–Whitney).
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Fig. 3. Kaplan–Meier survival analysis of the different
clusters showing significant differences (P  0.01, log
rank). Cluster 1, representedby coactivationofTTF-1and
NKX2–8 had the worst prognosis compared to the sur-
vival patterns of those in clusters 2 and 3 (P 0.002 and
P 0.02, log rank, respectively). The number of patients
at risk by clusters at 0, 20, 40, 60, and 80months is shown
for clarity (Left).
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ularly in NSCLC. Platinum compounds constitute the backbone of
combination chemotherapy in NSCLC, although only 30–40% of
patients with NSCLC respond to cisplatin-based therapy (27).
Using a previously validated gene expression signature of cisplatin
resistance, we compared the correlation between the likelihood of
TTF-1/NKX2–8 coactivation (the worst prognosis cohort) and
cisplatin resistance in a cohort of 56 lung cancer cell lines. As shown
in Fig. 5A, clusters similar to those seen in patient samples were also
seen in this large cohort of NSCLC cell lines. More importantly,
PAX9 activation was associated with cisplatin sensitivity while
coactivation of TTF-1 andNKX2–8 had a direct linear relationship
with likelihood of cisplatin resistance (P 0.0001, r 0.87, Fig. 5B
Left). This association was confirmed using drug sensitivity assays,
wherein the EC50s of cisplatin in the cluster of NSCLC cell lines
that showed coactivation of TTF-1 and NKX2–8 were significantly
higher than in the cluster of cell lines that did not demonstrate
activation of TTF-1 andNKX2–8 (P 0.02, r 0.80, Fig. 5BRight),
and is consistent with our previous observation. In our prior work,
we used the amplified NCI-H2170 cell system of the squamous cell
carcinoma subtype (which lacks transcription of TTF1) to test the
tumor maintenance function of NKX2–8 (and PAX9) by stably
expressing small hairpin RNA (shRNA) to knock down the protein
expression of NKX2–8 (or PAX9) (5). In this study, H2170 was
found to have coactivation ofNKX2–8 andTTF-1 pathways and the
H2170 transfectant cells of knocked-down expression of NKX2–8
presented an increased sensitivity to cisplatin (data not shown), in
line with our statistical prediction and experimental observation
that coactivation of TTF-1/NKX2–8 positively correlates with cis-
platin resistance.
To determine if the coactivation of TTF-1/NKX2–8 was corre-
lated with other commonly used chemotherapy agents in the
treatment ofNSCLC,we examined the sensitivity of the lung cancer
cell lines with coactivation of TTF-1/NKX2–8 to other cytotoxic
agents commonly used as therapeutic options in patients with
NSCLC (i.e., pemetrexed, paclitaxel, gemcitabine, and vinorel-
bine). Fig. S8 shows that coactivation of TTF-1/NKX2–8 is associ-
ated with resistance to taxanes, gemcitabine, and vinorelbine (data
not shown) but was positively correlated with antifolate therapy
with pemetrexed (P 0.03, r0.68), suggesting that pemetrexed
should be considered in the initial treatment for this cohort of
patients. This finding might explain, at least in part, the increased
clinical response of lung adenocarcinoma to pemetrexed.
Discussion
The capacity to understand biological complexity is often limited by
the ability to define relevant phenotypes. There is perhaps no better
example of this challenge than that seen in cancer, in particular lung
cancer.More than 180,000 new patients are diagnosedwithNSCLC
each year and 150,000 lung cancer-related deaths occur annually
(28), yet only minimal advances in therapeutic strategies that
significantly alter patient outcomehave been observed over the past
2 decades. This is likely due to the complexity of the oncogenic
process that involves the somatic acquisition of large numbers of
mutations, coupled with the varied host genetic constitution, which
produces a disease of enormous complexity that is extremely
difficult to characterize and treat effectively.
Traditional methods of characterizing tumors rely on gross visual
information (size of the tumor, degree of spread, histological
characteristics of the tumor) that is coupled to represent the TNM
staging system.Although these tools do provide a capacity to define
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Fig. 4. (A) Independent validation (n214) of thepoorprognosis associated
with coactivation of TTF-1 and NKX2–8. Box and whisker plots of survival are
plotted against the probability of samples being classified as having high
expression of TTF-1 andNKX2–8. Patients represented by cluster 1 (high TTF-1
and NKX2–8) have a significantly poorer outcome when compared to cluster
3 (high TTF-1 and PAX9, Left) and confirmed in independent Kaplan–Meier
survival analysis (Right). (B) Box and whisker plots of survival plotted against
the probability of samples being classified as having high expression of TTF-1
and NKX2–8. Patients represented by cluster 1 (high TTF-1 and NKX2–8) have
a significantly poorer outcomewhen compared cluster 2 (highNKX2–8 alone,
Left) and confirmed in independent Kaplan–Meier survival analysis (Right).
Table 1. Univariate and multivariate Cox proportional hazards
models of clinical, pathologic, and genomic variables
Hazard
ratio
Lower
95% CI
Upper
95% CI P-value
Univariate Cox proportional hazards model
Age 1.02 0.99 1.05 0.2175
Tumor size 1.24 1.07 1.44 0.0041
Gender 1.05 0.57 1.92 0.8797
Histologic subtype 1.02 0.57 1.83 0.9499
Vascular invasion 2.89 1.55 5.39 0.005
Lymphatic
invasion
2.49 1.21 5.15 0.0106
Lymph node status 1.96 1.05 3.67 0.0311
Pleural invasion 1.69 0.81 3.52 0.1544
Pathologic stage
Stage I/stage II 1.64 0.82 3.3 0.004
Stage I/stage III 5.62 2.12 14.86
Genomic cluster
Cluster 2/cluster 1 0.28 0.12 0.66 0.0095
Cluster 3/cluster 1 0.45 0.22 0.92
Cluster 4/cluster 1 0.83 0.34 2.02
Multivariate Cox proportional hazards model
Hazard
ratio
Lower
95%CI
Upper
95%CI P-value
Tumor size 1.22 1.02 1.46 0.03
Vascular invasion 2.50 0.97 6.47 0.07
Lymphatic
invasion
0.93 0.3 2.92 0.90
Lymph node status 0.78 0.27 2.3 0.65
Pathologic stage
Stage I/stage II 1.42 0.45 4.42 0.11
Stage I/stage III 4.87 1.09 21.84 0.01
Genomic cluster
Cluster 2/cluster 1 0.33 0.13 0.86 0.03
Cluster 3/cluster 1 0.64 0.26 1.54
Cluster 4/cluster 1 1.28 0.45 3.66
Only significant factors with univariate P  0.05 were included in the
multivariate model. Likelihood-ratio test against full model: P  0.005. The
likelihood-ratio test was done for the multivariate model with and without a
genomic cluster. CI, confidence interval.
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tumor subgroups with distinct biology, it is abundantly clear that
these classifications are imprecise, creating heterogeneous group-
ings of tumors and patients. Numerous examples can now be found
where gene expression profiles have been able to dissect tumor
subtypes (29, 30). The use of gene expression signatures as surro-
gate phenotypes has been particularly important, linking diverse
experimental systems that dissect the complexity of biological
systems in a way that was not previously feasible (31, 32). However,
none of these studies to date have addressed the potential impact
of specific developmental pathways on defining cancer phenotypes.
It is very likely that tissue-specific developmental pathways may be
critical in dissecting subtypes of cancer and may complement
current classification systems. Here we report on the role of
biological activities defined by the developmental oncogenes
TTF-1,NKX2–8, and PAX9 in lung cancer. All 3 genes are localized
to a unique, recurrent lung cancer amplicon at 14q13.3. Given its
essential function in lung development and relative restrictive
expression in lung tissue, TTF-1 is an appealing candidate as a cell
lineage-survival oncogene in lung cancer, similar to the MITF
oncogene specific to melanoma (2, 8). However, our recent dis-
covery of TTF-1, NKX2–8, and PAX9 as coamplified oncogenes
with functional synergism suggests that the 14q13.3 amplicon in
lung cancer provides selective advantage to tumor cells by way of
activation ofmultiple oncogenes, not justTTF-1 (5). Intriguingly, in
this present study, simultaneous activation of TTF-1 and NKX2–8
pathways was associated with poor survival, in contrast to activation
of individual genes that did not have prognostic significance. This
finding not only echoes our thesis of multiple collaborating driver
genes at the 14q13.3 amplicon, but also potentially sheds light on the
prognostic value of TTF-1 protein expression, which has thus far
been controversial (9, 33, 34). We believe that the prognostic
relevance of TTF-1 is best evaluated with consideration of its
oncogenic collaborator,NKX2–8. Furthermore, although the prog-
nostic significance of TTF-1 and NKX2–8 coactivation was vali-
dated in 2 large patient data sets and the impact on survival in early
stage NSCLC was found to be independent of standard clinico-
pathologic variables such as tumor size and stage (in the univariate
and multivariate analyses shown in Table 1), we emphasize, how-
ever, that there are several approaches to refining prognosis in early
stage NSCLC and the aims of this study were not to develop yet
another prognostic model. Instead, in the present context, we use
survival merely as a phenotype to demonstrate the biologic rele-
vance of TTF-1 and NKX2–8 coactivation in lung tumors. To
further elaborate, 3 large studies in lung cancer have been de-
scribed, all of which were specifically designed to find a prognostic
gene signature in early stageNSCLC using supervised classification
on gene expression data from lung tumor samples with known
clinical outcomes (25, 35, 36). Although the number of genes that
overlap between the 3 independently derived gene sets is minimal,
recent data suggest that because all 3 gene signatures could be
independently validated in large patient cohorts (25, 35, 36), it is
more likely that these gene signatures use different reporter genes
to monitor the same biological pathways or processes. When
comparing the pathways involved in the TTF-1 and NKX2–8
signatures, coactivation is associated with a higher likelihood of
recurrence in our present study. In addition, several biologically
relevant pathways are now identified (e.g., MAPKinase signaling,
JAK/STAT signaling, Wnt signaling, etc.) that are common among
the 3 previously described signatures of recurrence involved in
activation of TTF-1 andNKX2–8 (Table S2). Despite this observed
overlap in biologic pathways, it is important to note that none of the
prognostic models described to date, including our own previous
work (25), have shown predictive ability in being able to identify
patients resistant to standard cytotoxic therapy or sensitive to
specific targeted strategies.
The ability to identify a poor prognosis group of patients with
early stage NSCLC characterized by NKX2–8 and TTF-1 coacti-
vation whose survival pattern mimics that of patients with more
advanced disease (Fig. S4) suggests that platinum-based chemo-
therapy, the standard of care for patients with advanced disease,
may be beneficial in this ‘‘high-risk’’ group as well. However, in
sharp contrast, we found that patients defined by the poor prognosis
pattern (of TTF-1 and NKX2–8 coactivation) were in fact more
likely to be resistant to cisplatin therapy. This suggests that a
rational strategy to targeted therapy in the high-risk phenotype
represented by NKX2–8 and TTF-1 coactivation is needed to treat
this cohort of patients. We also emphasize that although these
findings are encouraging, prospective validation strategies that are
currently being initiated are needed before implementation into
clinical practice.
In conclusion, the developmental oncogenes TTF-1, NKX2–8,
and PAX9 are important biologically and clinically in lung cancer
initiation and progression. Gene signatures reflecting the status of
these transcription factors and patterns have prognostic and pre-
dictive value andmay provide a rational approach to individualizing
therapeutic options for a given patient with NSCLC.
Methods
Overexpression of NKX2–8, PAX9, and TTF-1. Oncogene-immortalized, prema-
lignant normal human lungepithelium (BEAS-2B)was purchased fromAmerican
Type Cell Collection. Retrovirus-mediated gene transfer was performed as de-
scribed previously (5) with expression vectors bearing each individual transcrip-
tion factor and 1 of 3 types of selection markers: puromycin, hygromycin, or
blasticidin. In each instance, cells were harvested for preparation of total RNA.
Infections of each individual transcription factor were performed 10 times to
generate sufficient consistent data for pattern analysis. Quantitative assays in-
cludingWestern analysis and RT-PCR were performed to evaluate the extent of
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Fig. 5. (A) Unsupervised hierarchical clustering of 56
lung cancer cell lines identifies unique patterns of
TTF-1, NKX2, and PAX9 coactivation (red, high level of
activation; blue, low level of activation) consistent
with patterns seen in tumor samples (Fig. 3). Predicted
probability of cisplatin resistance in the individual lung
cancer cell lines is plotted beneath the predicted prob-
abilities of transcription factor coactivation (red, resis-
tance to cisplatin; blue, sensitive to cisplatin). *, KRAS
and EGFRmutations. (B) (Left) A linear regression anal-
ysis of the predicted probability of cisplatin resistance
plotted against the predicted probability of transcrip-
tion factor coactivation of NKX2–8 and TTF-1 (dashed
box in A) reveals a positive correlation (P  0.0001).
(Right) A linear regression analysis demonstrates a
significant relationship between the EC50 of cisplatin
and the predicted probability of transcription factor
coactivation ofNKX2–8 and TTF-1 (dashed box inA) in
lung cancer cell lines (P  0.02).
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overexpression and activation of TTF-1,NKX2–8, and PAX9 (Fig. 1A). Anti-TTF-1,
anti-NKX2–8, and anti-PAX9 antibodies were purchased from abCam, Invitro-
gen, and GenWay, respectively.
Clinical Data. The ‘‘discovery’’ data set consists of 91 early stage NSCLC tumors
(Ia/Ib, IIa/IIb, and IIIa) (GSE3141) identified fromtheDukeLungCancer Prognostic
Laboratory (10). This data set represents equal numbers of squamous and ade-
nocarcinoma samples. The validation sample set included 214 samples: 84 lung
adenocarcinomas (GSE3593) (25) and 130 lung squamous cell carcinomas
(GSE4573) (26). Details of the relevant demographic and clinical information by
data set are shown in Table S3.
Gene Expression Arrays. Total RNA from stable transfectant cells overexpressing
each individual transcription factor was extracted using the QiaShredder and
Qiagen RNeasy Mini kit. RNAs were quantified using a Nanodrop ND-1000
spectrophotometer (Nanodrop Technologies) and quality was assessed with an
Agilent 2100 Bioanalyzer. Total RNAs were amplified by a modified Eberwine
technique(37),usingaMessageAmpIIkit (Ambion)for2roundsofamplification.
The resulting biotin-labeled RNA samples were then hybridizedwith Affymetrix
U133Plus2.0 GeneChip arrays according to the manufacturer’s instructions. All
analyses were performed in a minimal information about a microarray experi-
ment (MIAME)-compliant fashion, as defined in the guidelines established by
MGED (www.mged.org). The gene expression data used in the analyses are
available at GEO (GSE9212, GSE3141, GSE3593, and GSE4573).
Gene Expression Analysis. Gene expression data obtained from cell lines trans-
fected with each individual transcription factor were used to populate a matrix
withMATLAB software. Statistical modeling representing activation of the indi-
vidual transcription factors (NKX2–8, PAX9, and TTF-1) was performed using
metagene construction and binary prediction analysis, as described previously
(10, 25, 38). Gene expression signatures that reflect the activity of a given
transcription factor were applied to a clinically annotated data set of 91 tumor
samples (GSE3141) to predict patterns of transcription factor activation. Predic-
tions of transcription factor pathway activation within the tumor samples were
evaluatedtoproduceestimatedrelativeprobabilitiesandassociatedmeasuresof
uncertainty of transcription factor activation across the validation set. An esti-
mated probability of 0.5 was classified as high probability of transcription factor
activation and aprobability of0.5was classified as lowprobability of transcrip-
tion factor activation. Applications of the transcription factor predictors to other
data sets (GSE4573, GSE3593) and the gene expression-based predictor of cispla-
tin resistance (38) to lung cancer cell lines and lung tumor data sets (GSE3141)
were performed as described above. See SI Methods for complete details.
Hierarchical clustering using the gene pattern software (http://www.broad.
mit/edu/cancer/software/genepatter) based on the probability of transcription
activation of the tumor samples was used to generate clusters with coactivation
of specific transcription factors. Specifically, the clustering was performed using
a complete linkagewith a Pearson correlationmetric method on the preprocess
data toorganize all of thedata elements into a single treewith thehighest levels
of the tree representing the discovered classes (29).
Standard Kaplan–Meier mortality curves and their significance level were
generated to evaluate the prognostic role of individual transcription factors and
in clusters of patientswith coactivated transcription factors, using the graphpad
software. The log-rank test was used to assess the differences between the
survival curves and to calculate the nominal P-values between groups.
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